Oral vinorelbine in the treatment of non-small cell lung cancer: Rationale and implications for patient management

Richard J. Gralla, Ulrich Gatzemeier, Vittorio Gebbia, Rudolf Huber, Mary O'Brien, Christian Puozzo

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Vinorelbine is an established treatment for advanced non-small cell lung cancer (NSCLC), both as a single agent and in combination chemotherapy. Recently, an oral form of this agent has been developed. Before accepting an established agent in a different administration form, rigorous testing is required to answer such questions as reliable bioavailability, continued safety and preservation of efficacy. In addition, an oral agent must provide patient convenience and acceptance, while being an economically sound approach. Oral vinorelbine was found to have acceptable and reliable pharmacokinetic profiles at clinically relevant dosage levels. Oral vinorelbine was found to have approximately 40% bioavailability; thus, a dose of 80 mg/m2 orally is the equivalent of 30 mg/m2 intravenously, and 60 mg/m2 orally is the equivalent of 25 mg/m2 intravenously. Studies also concluded a lack of food effect on the administration of oral vinorelbine. In addition, no drug-drug interactions were found with variety of commonly used antineoplastic agents. Vinorelbine, either orally or intravenously, has been investigated in randomised phase II trials as a single agent and in combination with cisplatin or carboplatin in patients with NSCLC. In general, response and survival results with oral vinorelbine appeared similar to the intravenous agent. Adverse-effect profiles were also similar for the two formulations. Clearly, the issue of venous irritation does not exist with oral vinorelbine; however, nausea and vomiting were more frequent when vinorelbine was administered orally compared with intravenously when no planned antiemetic therapy is given.

Original languageEnglish (US)
Pages (from-to)1403-1410
Number of pages8
JournalDrugs
Volume67
Issue number10
DOIs
StatePublished - 2007
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Cells
Therapeutics
Biological Availability
Drug interactions
Pharmacokinetics
Chemotherapy
Antiemetics
vinorelbine
Carboplatin
Combination Drug Therapy
Drug Interactions
Antineoplastic Agents
Nausea
Cisplatin
Vomiting
Oral Administration
Acoustic waves
Safety
Food

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Oral vinorelbine in the treatment of non-small cell lung cancer : Rationale and implications for patient management. / Gralla, Richard J.; Gatzemeier, Ulrich; Gebbia, Vittorio; Huber, Rudolf; O'Brien, Mary; Puozzo, Christian.

In: Drugs, Vol. 67, No. 10, 2007, p. 1403-1410.

Research output: Contribution to journalArticle

Gralla, RJ, Gatzemeier, U, Gebbia, V, Huber, R, O'Brien, M & Puozzo, C 2007, 'Oral vinorelbine in the treatment of non-small cell lung cancer: Rationale and implications for patient management', Drugs, vol. 67, no. 10, pp. 1403-1410. https://doi.org/10.2165/00003495-200767100-00003
Gralla, Richard J. ; Gatzemeier, Ulrich ; Gebbia, Vittorio ; Huber, Rudolf ; O'Brien, Mary ; Puozzo, Christian. / Oral vinorelbine in the treatment of non-small cell lung cancer : Rationale and implications for patient management. In: Drugs. 2007 ; Vol. 67, No. 10. pp. 1403-1410.
@article{5b64ca9f8071483fb149bb2f1af8e2b0,
title = "Oral vinorelbine in the treatment of non-small cell lung cancer: Rationale and implications for patient management",
abstract = "Vinorelbine is an established treatment for advanced non-small cell lung cancer (NSCLC), both as a single agent and in combination chemotherapy. Recently, an oral form of this agent has been developed. Before accepting an established agent in a different administration form, rigorous testing is required to answer such questions as reliable bioavailability, continued safety and preservation of efficacy. In addition, an oral agent must provide patient convenience and acceptance, while being an economically sound approach. Oral vinorelbine was found to have acceptable and reliable pharmacokinetic profiles at clinically relevant dosage levels. Oral vinorelbine was found to have approximately 40{\%} bioavailability; thus, a dose of 80 mg/m2 orally is the equivalent of 30 mg/m2 intravenously, and 60 mg/m2 orally is the equivalent of 25 mg/m2 intravenously. Studies also concluded a lack of food effect on the administration of oral vinorelbine. In addition, no drug-drug interactions were found with variety of commonly used antineoplastic agents. Vinorelbine, either orally or intravenously, has been investigated in randomised phase II trials as a single agent and in combination with cisplatin or carboplatin in patients with NSCLC. In general, response and survival results with oral vinorelbine appeared similar to the intravenous agent. Adverse-effect profiles were also similar for the two formulations. Clearly, the issue of venous irritation does not exist with oral vinorelbine; however, nausea and vomiting were more frequent when vinorelbine was administered orally compared with intravenously when no planned antiemetic therapy is given.",
author = "Gralla, {Richard J.} and Ulrich Gatzemeier and Vittorio Gebbia and Rudolf Huber and Mary O'Brien and Christian Puozzo",
year = "2007",
doi = "10.2165/00003495-200767100-00003",
language = "English (US)",
volume = "67",
pages = "1403--1410",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "10",

}

TY - JOUR

T1 - Oral vinorelbine in the treatment of non-small cell lung cancer

T2 - Rationale and implications for patient management

AU - Gralla, Richard J.

AU - Gatzemeier, Ulrich

AU - Gebbia, Vittorio

AU - Huber, Rudolf

AU - O'Brien, Mary

AU - Puozzo, Christian

PY - 2007

Y1 - 2007

N2 - Vinorelbine is an established treatment for advanced non-small cell lung cancer (NSCLC), both as a single agent and in combination chemotherapy. Recently, an oral form of this agent has been developed. Before accepting an established agent in a different administration form, rigorous testing is required to answer such questions as reliable bioavailability, continued safety and preservation of efficacy. In addition, an oral agent must provide patient convenience and acceptance, while being an economically sound approach. Oral vinorelbine was found to have acceptable and reliable pharmacokinetic profiles at clinically relevant dosage levels. Oral vinorelbine was found to have approximately 40% bioavailability; thus, a dose of 80 mg/m2 orally is the equivalent of 30 mg/m2 intravenously, and 60 mg/m2 orally is the equivalent of 25 mg/m2 intravenously. Studies also concluded a lack of food effect on the administration of oral vinorelbine. In addition, no drug-drug interactions were found with variety of commonly used antineoplastic agents. Vinorelbine, either orally or intravenously, has been investigated in randomised phase II trials as a single agent and in combination with cisplatin or carboplatin in patients with NSCLC. In general, response and survival results with oral vinorelbine appeared similar to the intravenous agent. Adverse-effect profiles were also similar for the two formulations. Clearly, the issue of venous irritation does not exist with oral vinorelbine; however, nausea and vomiting were more frequent when vinorelbine was administered orally compared with intravenously when no planned antiemetic therapy is given.

AB - Vinorelbine is an established treatment for advanced non-small cell lung cancer (NSCLC), both as a single agent and in combination chemotherapy. Recently, an oral form of this agent has been developed. Before accepting an established agent in a different administration form, rigorous testing is required to answer such questions as reliable bioavailability, continued safety and preservation of efficacy. In addition, an oral agent must provide patient convenience and acceptance, while being an economically sound approach. Oral vinorelbine was found to have acceptable and reliable pharmacokinetic profiles at clinically relevant dosage levels. Oral vinorelbine was found to have approximately 40% bioavailability; thus, a dose of 80 mg/m2 orally is the equivalent of 30 mg/m2 intravenously, and 60 mg/m2 orally is the equivalent of 25 mg/m2 intravenously. Studies also concluded a lack of food effect on the administration of oral vinorelbine. In addition, no drug-drug interactions were found with variety of commonly used antineoplastic agents. Vinorelbine, either orally or intravenously, has been investigated in randomised phase II trials as a single agent and in combination with cisplatin or carboplatin in patients with NSCLC. In general, response and survival results with oral vinorelbine appeared similar to the intravenous agent. Adverse-effect profiles were also similar for the two formulations. Clearly, the issue of venous irritation does not exist with oral vinorelbine; however, nausea and vomiting were more frequent when vinorelbine was administered orally compared with intravenously when no planned antiemetic therapy is given.

UR - http://www.scopus.com/inward/record.url?scp=34347375530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347375530&partnerID=8YFLogxK

U2 - 10.2165/00003495-200767100-00003

DO - 10.2165/00003495-200767100-00003

M3 - Article

C2 - 17600389

AN - SCOPUS:34347375530

VL - 67

SP - 1403

EP - 1410

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 10

ER -